Medtronic (NYSE:MDT) responded to a study presented this week which highlighted usability concerns with its MiniMed 670G automated insulin pump, writing that the company had “made many enhancements to the system since the study was done which would likely mitigate many of the issues experienced.”
Earlier this week, physicians from Boston Children’s Hospital reported that nearly one-fifth of participants in a real-world study of the MiniMed 670G stopped using the system within months of it being prescribed, citing dissatisfaction with the technical demands of the system.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic responds to usability concerns for its MiniMed 670G insulin pump appeared first on MassDevice.
from MassDevice https://ift.tt/2HSGCTe
Cap comentari:
Publica un comentari a l'entrada